Old Drugs for New Indications in Cardiovascular Medicine
| Autor: | Robert S. Rosenson, Yaron Arbel, Alanna Weisman, Michael E. Farkouh, Wael Abuzeid |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Allopurinol
Anti-Inflammatory Agents Inflammation 030204 cardiovascular system & hematology Bioinformatics 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Animals Humans Colchicine Pharmacology (medical) 030212 general & internal medicine Pharmacology business.industry Atherosclerotic cardiovascular disease Cardiovascular Agents General Medicine Clinical trial Methotrexate Treatment Outcome chemistry Cardiovascular Diseases medicine.symptom Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiovascular Drugs and Therapy. 32:223-232 |
| ISSN: | 1573-7241 0920-3206 |
| Popis: | Inflammation participates in the initiation and progression of atherosclerotic cardiovascular disease, and it is a critical inciting factor leading to acute ischemic events. Evidence has shown that certain anti-inflammatory medications used to treat non-atherosclerotic inflammatory diseases reduce cardiovascular events. This article reviews evidence that commonly used anti-inflammatory therapies (colchicine, allopurinol, methotrexate), reduce cardiovascular events. We discuss potential mechanisms of action, efficacy, and safety of these therapies and propose a clinical trials design to investigate their efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink